Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
44.00
+1.60 (3.77%)
Apr 28, 2026, 4:08 PM HKT
64.49%
Market Cap 54.51B
Revenue (ttm) 7.60B
Net Income (ttm) 988.05M
Shares Out n/a
EPS (ttm) 1.15
PE Ratio 55.17
Forward PE 50.67
Dividend 0.32 (0.74%)
Ex-Dividend Date Jun 12, 2025
Volume 2,693,700
Average Volume 1,901,391
Open 41.74
Previous Close 42.40
Day's Range 41.74 - 44.48
52-Week Range 24.55 - 60.60
Beta 0.68
RSI 54.32
Earnings Date Mar 30, 2026

About HKG:3347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, includ... [Read more]

Sector Healthcare
Founded 2004
Employees 11,130
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3347
Full Company Profile

Financial Performance

In 2025, HKG:3347's revenue was 6.83 billion, an increase of 3.48% compared to the previous year's 6.60 billion. Earnings were 887.89 million, an increase of 119.15%.

Financial numbers in CNY

News

There is no news available yet.